Difference between revisions of "Traebert M, et al, Eur J Pharmacol (2004), cited as Ref 35 in DOI: 10.1007/s11886-020-01293-2 (Q11029)"
Jump to navigation
Jump to search
(Created claim: Published In Name String (P102): Eur J Pharmacol, #quickstatements; #temporary_batch_1592836225919) |
(Created claim: DOI Identifier (P138): 10.1016/j.ejphar.2003.11.003, #quickstatements; #temporary_batch_1592836326594) |
||
| Property / DOI Identifier | |||
| + | |||
| Property / DOI Identifier: 10.1016/j.ejphar.2003.11.003 / rank | |||
| + | Normal rank | ||
Revision as of 14:33, 22 June 2020
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Traebert M, et al, Eur J Pharmacol (2004), cited as Ref 35 in DOI: 10.1007/s11886-020-01293-2
|
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
|
Statements
Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells (English)
0 references
2004
0 references
Traebert M
0 references
Dumotier B
0 references
Meister L
0 references
Hoffmann P
0 references
Dominguez-Estevez M
0 references
Suter W
0 references
Eur J Pharmacol
0 references
